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ABSTRACT 
Ketosis is a major metabolic disorder of dairy cattle in the United States, affecting an 
estimated 40% of all lactations in the industry (Geishauser et al., 2001). There are various 
viewpoints on whether it is cost effective to treat subclinical cases of ketosis (SCK) with 
propylene glycol (PPG) and dextrose in comparison to treating animals that become clinically 
ketotic (McArt et al., 2011, 2013). For this trial, there was a control group and two treatment 
groups. Control cows had blood β-hydroxybutarate (BHBA) concentrations <1.2 mM/L and did 
not receive treatment. Treatment 1 cows were deemed subclinically ketotic, defined by a blood 
BHBA of 1.2 to 2.9 mM/L and received 250 mL 50% dextrose solution intravenously and 300 
mL PPG orally for 3 d. Treatment 2 cows also were subclinical (same criteria as Trt 1) but did 
not receive the PPG and dextrose. Cows with >2.9 mM/L BHBA were not enrolled in the trial. 
To determine treatment, blood was drawn from the tail vein/artery at 4 d in milk (DIM) and 
tested for BHBA using a Precision Xtra Meter. Blood non-esterified fatty acids (NEFA) 
concentrations and BCS (1= thin, 5=fat) were recorded -14 to -3 d pre-partum. Pre-partum 
NEFA concentrations were similar between Trt 1 and 2 but decreased for control (309, 293, and 
243 μEq/mL, respectively). BHBA at 4 DIM was similar for Trt 1 and 2 but less for control 
(1.66, 1.70, and 0.70 mM/L, respectively), with a similar pattern at 11 DIM (1.29, 1.43, and 0.71 
mM/L, respectively).  BCS at 11 DIM was similar for Trt 1 and control cows (3.37 vs 3.34) but 
less for Trt 2 cows (3.29). Milk yield was similar for control and Trt 1 cows, but milk yield was 
lesser for Trt 2 cows compared to control cows. This increased milk production from Trt 1 
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versus Trt 2 on a daily basis equals $0.40/day ($20/cwt milk price). Since it cost the farm $5.90 
to treat each case of subclinical ketosis, the increased milk production would have to be 
sustained for 15 days to cover the cost of treatment. The increased milk yield is an average over 
90 DIM, so the return over cost of treating subclinical ketosis was $30.10/cow for this period 
(Trt 1 produced 81 kg more milk than Trt 2). These results lead us to reach the conclusion that it 
is cost-effective to treat subclinical ketosis in recently fresh dairy cows. 
INTRODUCTION 
Ketosis is a major metabolic disorder of dairy cattle in the United States, affecting an 
estimated 40% of all lactations in the industry between clinical and subclinical cases (Geishauser 
et al., 2001). Clinical ketosis is also known as hyperketonemia and is characterized by high 
levels of ketones in the blood and is often manifested as lethargic and anoerexic behavior in the 
peri-partum dairy cow (Xia et al, 2012). Subclinical ketosis is more difficult to monitor because 
it is not noticeable to the eye without a blood, milk, or urine test. Even though it is not outwardly 
noticeable, it is still estimated to cost the farmer $78/case due to both the direct and indirect costs 
associated with it (Geishauser et al., 2001).  
This common disorder is caused when the body is in a state of negative energy balance, 
usually immediately post calving, when the demand for glucose and energy increases immensely 
and the body starts to mobilize the body’s fat stores. Fat mobilization releases NEFA into the 
blood, where they can be used as a fuel source for several tissues, including muscle and can also 
be used by the mammary gland for fat synthesis (Palmquist et al., 1969). A portion of the NEFA 
released from lipolysis will be removed from the blood by the liver and metabolized by one of 
three pathways to help make up for the negative energy balance experienced in early lactation 
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(Drackley and Anderson, 2006). The liver can completely oxidize these fatty acids for energy, it 
can partially oxidize them to produce ketones, or the fatty acids can be packaged back as 
triglycerides and then incorporated into lipoproteins to go back to the tissues, or stored in the 
liver (Allen et al., 2013). The three most common ketones produced by the partial oxidation of 
fatty acids in the liver include acetone (AC), acetoacetate (ACAC), and BHBA and these three 
can be used for energy by some tissues, such as the brain, skeletal muscle, and cardiac muscles. 
This pathway is extremely important in the glucose sparing processes of the body that are of 
importance during periods of fasting and negative energy balance. Hepatic oxidation of fats, 
however, is believed to suppress appetite and reduce dry matter intake by inducing satiety (Allen 
et al., 2013). Depressing dry matter intake further confounds the original negative energy balance 
(NEB) issue and can send these animals on a downward trajectory if they are not treated.  
It has been shown that ketosis and NEB also have negative consequences on reproduction 
and immune function (Esposito et al., 2014). When the body loses control of the level of ketones 
in the blood, the high concentrations will lead to weight loss, lethargy, suppressed appetite and 
often a sweet smelling breath (McArt et al., 2013). It is generally accepted that clinical ketosis 
occurs when blood BHBA levels reach >3.0 mM/L. Subclinical ketosis is often defined as blood 
BHBA concentrations of >1.2 mMol/L and <3.0 mMol/L and  is considered to have a cost of 
$78/case (Geishauser et al., 2001). These animals show no “clinical” signs but have been shown 
to be predisposed to decreased milk production, reduced reproductive efficiency, and at risk for 
other metabolic diseases. Studies done at Cornell University (McArt et al., 2011) have shown 
that propylene glycol has merit as a treatment for subclinical ketosis, but research done at the 
University of Minnesota (Carrier et al., 2006) revealed that a combination of treatments 
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(propylene glycol, dextrose, dexamethasone, and niacin) is not always cost effective in the 
treatment of subclinical ketosis.  
The dairy farm used in this study had 3300 milk cows, and after reviewing the current 
research and expert opinions on treating subclinical ketosis, they were interested in determining 
the cost effectiveness of their current protocol.  At the time of the study, the farm was using a 
combination treatment of 250 mL of  50% dextrose solution IV and 300 mL PPG orally to treat 
any cows with blood BHBA concentrations >1.2 mMol/L. The purpose of this trial was to 
determine the cost effectiveness of treating for subclinical ketosis in Holstein dairy cows. We 
hypothesized that prepartum NEFA would be higher for cows that experienced subclinical 
ketosis after parturition than control cows. In addition, we expected that control cows and treated 
cows with subclincial ketosis would have higher milk yield than untreated cows. 
METHODS 
Blood samples were drawn from the tail vein/artery and body condition scores (1= thin, 
5=fat) were taken on multiparous cows at -14 to -3 d pre-partum. The samples were centrifuged, 
the serum was pipetted off, and it was frozen until after the trial, when NEFA assays were 
conducted using a HR Series NEFA-HR (2) kit from Wako Diagnostics (Mountain View, CA). 
Cows were then enrolled into a treatment group at 4 DIM (4 d post-calving) when they received 
a health check that was consistent with on-farm protocols. There was a control and two treatment 
groups for this trial. Control cows (n=165) were multiparous, had <1.2 mM/L BHBA, appeared 
free from disease, and did not receive treatment. Treatment 1 cows (Trt 1) (n=58) were 
multiparous, deemed subclinically ketotic, defined by a BHBA of 1.2 to 2.9 mM/L but appeared 
otherwise healthy, and received 250 mL 50% dextrose solution intravenously on day 1 and 300 
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mL PPG orally for 3 d. Treatment 2 cows (Trt 2) (n=60) also were multiparous, subclinically 
ketotic (same criteria as Trt 1) and appeared otherwise healthy but did not receive the PPG and 
dextrose. Cows with >2.9 mM/L BHBA or any other diseases identified by the health check were 
not enrolled in the trial. Diseases and health issues that kept animals out of the trial at 4 DIM 
included lameness, mastitis, metritis with a fever, milk fever, and displaced abomasum. To 
determine treatment, blood was drawn from the tail vein/artery at 4 DIM and tested for BHBA 
concentration using a Precision Xtra Meter (Abbott Laboratories, Chicago, IL), and if BHBA 
was in the appropriate range and the cows fit the other health criteria, they were placed randomly 
into treatment 1 or 2 using the RAND function of Microsoft Excel. At 11 DIM, a second BHBA 
concentration was recorded as well as a BCS taken again and any animal with a BHBA >1.2 
mM/L was treated with dextrose and PPG. If any animal’s appearance warranted a health check, 
blood was drawn and checked for BHBA concentrations, a BCS was taken, and if the BHBA 
concentration was >1.2 mM/L BHBA, the animal was treated with dextrose and PPG regardless 
of the treatment group in which they were enrolled at 4 DIM. If a cow was re-checked after 6 
DIM (end of medication with PPG) but before 11 DIM, the cow had a second BHBA analysis 
and a BCS was assigned at the time of the second bleeding, so they did not get scored on 11 
DIM. Animals were followed for 90 DIM for recording of milk weights. Health events, including 
mastitis, lameness, and displaced abomasum, were recorded as well. BCS were taken at first 
breeding and reproduction data, including DIM at first breeding, were collected from Dairy 
Comp 305 (Valley Ag Software, Tulare, CA). Data were analyzed using the GLM procedure of 
SAS (SAS Institute, Inc., Cary, NC). Significance was declared at P< 0.05 and trends at P < 
0.10. 
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 Expenses associated with treating subclinical ketosis were obtained from the farm records 
and included labor, PPG, and dextrose. The costs of the Precision Xtra meter and test strips were 
not included because every cow gets checked at 4 DIM, as per the on-farm protocol. Labor cost 
of $13.00/hr was used. The price of the increased yield of milk was calculated using the average 
price of milk over the time the trial was conducted ($20/cwt).  
RESULTS 
Pre-partum NEFA concentrations were similar between Trt 1 and Trt 2 but less for 
control (316, 299, and 240 μEq/mL, respectively; Table 1). BCS for the three groups pre-partum 
were 3.47 for control cows, 3.62 for Trt 1, and 3.59 for Trt 2 with control cows having a lower 
BCS.  BHBA at 4 DIM was similar for Trt 1 and Trt 2 but less for control (1.66, 1.69, and 0.70 
mM/L, respectively), with a similar pattern at 11 DIM (1.34, 1.46, and 0.69 mM/L, respectively). 
BCS at 11 DIM was similar for Trt 2 and control cows (3.31 vs 3.33) but increased for Trt 1 
cows (3.45) (pre-partum BCS was used as a co-variant in this statistical analysis). Milk yield was 
similar for control and Trt 1 cows (42.7 and 42.1 kg/d, respectively) (Figure 1), but milk yield 
was decreased for Trt 2 cows (41.2 kg/d) compared to control cows. There was a trend (P = 0.06) 
for milk yield to be increased for Trt 1 versus Trt 2 cows. This increased milk production from 
Trt 1 versus Trt 2 on a daily basis equals $0.40/d ($20/cwt for milk price). Since it cost the farm 
$5.90 to treat each case of subclinical ketosis (Table 2), the increased milk production would 
have to be sustained for 15 days to cover the cost of treatment. The increased milk yield is an 
average over 90 DIM, so the return over cost of treating subclinical ketosis is $30.10/cow for this 
period (Trt 1 produced 81 kg more milk than Trt 2).  Services per conception did not vary across 
Trt 1, Trt 2 and Control (2.15, 1.89, and 1.98, respectively).  
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Table 1. Non-esterified fatty acids (NEFA), serum β-hydroxybutyrate (BHBA), body condition 
score (BCS), milk yield and services per conception for control and treatment cows (DIM = days 
in milk).
1
 
Variable Control TRT 1 TRT 2 SE 
Pre-partum NEFA, μEq/mL 240
b
 316
a
 299
a
 19 
Pre-partum BCS 3.47
b
 3.62
a
 3.59
a
 0.03 
4 DIM BHBA, mM/L 0.70
b
 1.66
a
 1.69
a
 0.04 
11 DIM BHBA, mM/L 0.69
b
 1.34
a
 1.46
a
 0.10 
11 DIM BCS 3.33
a
 3.45
b
 3.31
a
 0.03 
Milk, kg/d (wk 1-13) 42.7
b,c
 42.1
ab,c
 41.2
a,d
 1.2 
Services per conception 1.98 2.15 1.89 0.15 
1
Control= <1.2 mM/L BHBA, TRT 1 = 1.2 to 2.9 mM/L BHBA  received propylene glycol (PPG) and dextrose, and 
TRT 2 = 1.2 to 2.9 mM/L BHBA no PPG and dextrose; SE = standard error. 
ab
Means in the same row differ (P < 0.05) 
cd
Means in the same row tended to differ (P = 0.06) 
 
Table 2. Cost of treatment per case of subclinical ketosis and net return on investment of 
increased milk yield.  
Item Unit $/unit dose/unit $/dose dose/case $/case 
Propylene Glycol (PPG) $900.00  690 $0.81  3 ($2.43) 
Dextrose $2.36  2 $1.18  1 ($1.18) 
Labor for PPG $13.00  40 $0.33  3 ($0.99) 
Labor for Dextrose $13.00  10 $1.30  1 ($1.30) 
Total Cost per Case     ($5.90) 
Revenue from Increased Milk 
Yield 
    $36.00  
Net Return on Investment per 
case 
    $30.10  
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Figure 1. Milk yield for week of lactation by control and treatment cows.  
 
DISCUSSION AND CONCLUSIONS 
It has been shown in previous studies that elevated blood NEFA concentrations in close-
up cows have a strong correlation to postpartum metabolic disorders, such as ketosis and DA. 
Elevated pre-partum NEFA concentrations are also associated with less milk production and 
decreased reproductive performance (Ospina et al., 2010; McArt et al., 2013) . The results from 
the NEFA in our study was consistent with previous research as the two groups with increased 
BHBA concentration at 4 DIM both had increased NEFA concentrations pre-partum in 
comparison to the control, healthy cows. The blood BHBA concentrations of Trt 1 and Trt 2 
were similar at 4 DIM, which is what we expected, and the control group was significantly 
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decreased. At 11 DIM, the two groups that started out with subclinical ketosis still had similar 
levels of BHBA in their blood and were decreased then at 4 DIM. However, the BHBA levels at 
11 DIM were still, on average, in the subclinical range, although the standard error was greater 
than 4 DIM, suggesting a greater variation in levels at 11 DIM. These values still being above 
1.2 mM/L begs the question of whether this treatment did as much good as was hoped. In the 
study by McArt et al. (2013), the subclinical cows were given PPG until they had BHBA 
concentrations below 1.2 mM/L and was not restricted to just 3 d. 
The increased BCS at 11 DIM for Trt 1, about a tenth point greater, was as expected in 
comparison to Trt 2 given that Trt 1 were likely in a less NEB by receiving the IV of dextrose 
and three oral doses of PPG. Control animals had a BCS that was similar to Trt 2 at 11 DIM, and 
this is possibly because they started out with a decreased body condition and therefore were less 
predisposed to ketosis and also probably lost less condition. The less milk yield for Trt 2 
compared to control cows was as expected, concurrent with previous research whereby 
subclinical cows produced less milk during the lactation. One possible explanation for this is Trt 
2 cows likely consumed less dry matter while they were subclinically ketotic, which would result 
in less nutrients available for milk synthesis, even though they likely mobilized more adipose 
tissue in an attempt to support that milk yield. This decreased milk yield was consistent 
throughout the first 13 weeks of lactation (Figure 1). Milk yield for Trt 1 tended to be greater 
than for Trt 2 and even though the difference in milk yield only tended to be greater, it was very 
close to being statistically significant (P = 0.06) and with the animal numbers involved in this 
study and on the farm, this could still have large economic implications. The gain in milk yield 
returned $30.10/cow for the 90-d period, showing some economic benefit to continuing to treat 
cows with subclinical ketosis. Although energy balance and milk yield appeared to favor Trt 1 in 
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comparison to Trt 2, services per conception were similar, which may have occurred because 
subclinical ketosis is less likely to impact reproduction efficiency than clinical ketosis. Another 
consideration is, at the time the data were examined, not all the animals of all the groups had 
been confirmed pregnant, so perhaps after all animals become pregnant, there may be some 
significance that arises. There is research indicating that animals with an elevated blood BHBA 
concentration in the first three weeks post-partum are less likely to become pregnant after their 
first insemination (Walsh et al., 2007), so we expect some differences to arise.  
For the input costs and return on investment analyzed, the net return associated with 
medication and labor was favorable for the monitoring and treatment of subclinical ketosis with 
one day of intravenous dextrose and three days of oral PPG in this study.  
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